| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
22 |
/ |
2020 |
|
|
|
| |
Data sporządzenia: |
2020-10-13 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Awarding a Group Purchasing Agreement with Premier for CompuFlo® Epidural System and
CathCheck™
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer",
“Milestone"_ today announced that Milestone Scientific Inc., the licensor of computer-controlled
injection and drug delivery technology and the majority shareholder of Milestone Medical
Inc. has been awarded a group purchasing agreement for the CompuFlo® Epidural System
and CathCheck™ with Premier. Effective November 1, 2020, the new agreement allows
Premier members, at their discretion, to take advantage of special pricing and terms
pre-negotiated by Premier for the CompuFlo® Epidural System and CathCheck™.
Premier is a leading healthcare improvement company, uniting an alliance of approximately
4,100 U.S. hospitals and 200,000 other providers to transform healthcare. With integrated
data and analytics, collaboratives, supply chain solutions, and advisory and other
services, Premier enables better care and outcomes at a lower cost.
The Board of Directors of the Company is honored to have been selected by Premier,
a leading group purchasing organization, to offer its instruments throughout their
network. This agreement provides the enhanced access to Premier’s members and should
help accelerate the Issuer’s mission to become the standard of care. The Board of
Directors of the Company believes this agreement is further validation of the growing
awareness and importance of its instruments in improving health outcomes and lowering
costs for healthcare institutions.
The clinical and safety benefits of the CompuFlo® Epidural System are backed by extensive
published clinical data demonstrating significant reductions in epidural punctures
and complication rates. Moreover, the CompuFlo® instrument has been shown to significantly
reduce the total cost per hospital stay, providing a direct economic benefit to healthcare
institutions. Similarly, the CathCheck technology has the potential to transform the
administration of epidural procedures and subsequent monitoring of catheter placement
following an epidural procedure by confirming the placement of a catheter within 2
minutes, versus 20-40 minutes using conventional methods. This is especially important
during the COVID-19 pandemic, given its ability to minimize contact between the patient
and provider.
The Board of Directors of the Company would like to commend Premier for their leadership
in adopting new technologies that provide direct and measurable benefits to both physicians
and patients. The Board of Directors of the Issuer would also like to thank its team
at Milestone for their hard work in consummating this landmark agreement. The Board
of Directors of the Issuer believes this agreement will significantly advance the
plans for commercialization of the CompuFlo® Epidural System and CathCheck™ technology
in the United States.
|
|
|
RB_ASO: Awarding a Group Purchasing Agreement with Premier for CompuFlo® Epidural System and
CathCheck™
